It's Time to Move Forward

TransATAC Clinical Verification Study

Click here to access the TransATAC clinical verification study article, available through Journal of Clinical Oncology.

ABCSG-8 Clinical Validation Study

Click here to access the ABCSG-8 clinical validation study article.

Analytical Validation Study

Click here to access the analytical validation study, available through BMC Cancer.


Information contained within these publications include information related to FDA-cleared products but is not consistent with the FDA-cleared Package Insert. Please refer to the FDA-cleared Package Insert for product information.

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.